Lastly, the interest in tau immunotherapy for AD and tau-relevant neurodegenerative diseases has grown immensely over the past few years, perhaps in part, due to the failure of Aβ IT to reverse cognitive deficits in moderate-severe AD patients. This evidence concerns the gene MAPT and neurodegenerative disease.